Trial Profile
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of Vigil Engineered Autologous Tumor Cell Immunotherapy in Subjects With Stage IIIb-IV Ovarian Cancer in Clinical Complete Response Following Surgery and Primary Chemotherapy
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 23 Aug 2023
Price :
$35
*
At a glance
- Drugs Bi-shRNAfurin-GM-CSF-loaded tumour cell vaccine (Primary)
- Indications Endometrial cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- Acronyms VITAL
- Sponsors Gradalis
- 16 Aug 2023 Planned End Date changed from 1 Dec 2023 to 1 Dec 2025.
- 16 Aug 2023 Planned primary completion date changed from 1 Dec 2023 to 1 Dec 2025.
- 14 Jul 2023 Planned End Date changed from 1 Jul 2023 to 1 Dec 2023.